M
Marco Bonavia
Publications - 20
Citations - 1254
Marco Bonavia is an academic researcher. The author has contributed to research in topics: Asthma & Mepolizumab. The author has an hindex of 10, co-authored 18 publications receiving 1012 citations.
Papers
More filters
Journal ArticleDOI
Inhaler mishandling remains common in real life and is associated with reduced disease control
Andrea S. Melani,Marco Bonavia,Vincenzo Cilenti,Cristina Cinti,Marco Lodi,Paola Martucci,Maria Serra,Nicola Scichilone,Piersante Sestini,Maria Aliani,Margherita Neri +10 more
TL;DR: In this paper, the authors investigated the prevalence of inhaler mishandling in a large population of experienced patients referring to chest clinics; to analyze the variables associated with misuse and the relationship between inhaler handling and health-care resources use and disease control.
Journal ArticleDOI
Erratum to “Inhaler mishandling remains common in real life and is associated with reduced disease control” [Respir Med 105 (6) 2011 930–938]
Andrea S. Melani,Marco Bonavia,Vincenzo Cilenti,Cristina Cinti,Marco Lodi,Paola Martucci,Maria Serra,Nicola Scichilone,Piersante Sestini,Maria Aliani,Margherita Neri +10 more
Journal ArticleDOI
Italian real-life experience of omalizumab
Mario Cazzola,Gianna Camiciottoli,Marco Bonavia,C. Gulotta,A. Ravazzi,A. Alessandrini,Maria Filomena Caiaffa,A. Berra,Pietro Schino,P.L. Di Napoli,Rosario Maselli,Girolamo Pelaia,E. Bucchioni,Pierluigi Paggiaro,Luigi Macchia +14 more
TL;DR: The observed reduction of asthma-related events in particularly poorly controlled patients in this Italian real-life setting is consistent with the results of other observational studies.
Journal ArticleDOI
One year of mepolizumab. Efficacy and safety in real-life in Italy.
Diego Bagnasco,Marco Caminati,Francesco Menzella,Manlio Milanese,Giovanni Rolla,Carlo Lombardi,Caterina Bucca,Enrico Heffler,Giovanni Paoletti,Elisa Testino,Andrea Manfredi,Cristiano Caruso,Giuseppe Guida,Gianenrico Senna,Marco Bonavia,Anna Maria Riccio,Giorgio Walter Canonica,Giovanni Passalacqua +17 more
TL;DR: In this real-life setting, MEP confirmed its efficacy and safety profile, already shown in clinical trials, including concerning exacerbation rate, systemic steroids intake and safety.
Journal ArticleDOI
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry
Giorgio Walter Canonica,Luca Malvezzi,Francesco Blasi,Pierluigi Paggiaro,Marco Mantero,Gianenrico Senna,Enrico Heffler,Marco Bonavia,P. Caiaffa,Cecilia Calabrese,Gianna Camiciottoli,Cristiano Caruso,Stefano Centanni,Maria Elisabetta Conte,Angelo Corsico,Lorenzo Cosmi,Maria Teresa Costantino,Nunzio Crimi,Simona D’Alo,M D'Amato,S. Del Giacco,Elisabetta Favero,A. Farsi,B.P.M. Foschino,Gabriella Guarnieri,Giuseppe Guida,M. Latorre,Carolina Lombardi,Luigi Macchia,Francesco Menzella,Manlio Milanese,Paolo Montuschi,Eleonora Nucera,Roberta Parente,G. Passalacqua,Vincenzo Patella,G. Pelaia,Laura Pini,Fabio Luigi Massimo Ricciardolo,Luisa Ricciardi,Luca Richeldi,Erminia Ridolo,Giovanni Rolla,Pierachille Santus,Nicola Scichilone,Paolo Solidoro,Giuseppe Spadaro,Antonio Spanevello,Andrea Vianello,Mona-Rita Yacoub,Martina Zappa +50 more
TL;DR: OCS sparing is needed in patients with severe asthma, mainly in subjects with CRSwNP, adopting adequate strategies such as a better adherence to the treatment with inhaled therapy according to the GINA recommendations, the use of biologic agents and a multidisciplinary approach of the patient.